PortfoliosLab logoPortfoliosLab logo
RYTM vs. AVGO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RYTM vs. AVGO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rhythm Pharmaceuticals, Inc. (RYTM) and Broadcom Inc. (AVGO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RYTM achieves a -20.86% return, which is significantly lower than AVGO's 38.76% return.


RYTM

1D
0.43%
1M
-1.02%
YTD
-20.86%
6M
-19.04%
1Y
28.99%
3Y*
68.05%
5Y*
35.54%
10Y*

AVGO

1D
-0.49%
1M
15.06%
YTD
38.76%
6M
26.42%
1Y
88.09%
3Y*
83.13%
5Y*
61.98%
10Y*
43.87%
*Multi-year figures are annualized to reflect compound growth (CAGR)

RYTM vs. AVGO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
RYTM
Rhythm Pharmaceuticals, Inc.
-20.86%91.21%21.78%57.86%191.78%-66.43%29.49%-14.58%-7.50%-3.13%
AVGO
Broadcom Inc.
38.76%50.63%110.49%104.18%-13.27%56.48%44.88%29.05%2.18%6.13%

Correlation

The correlation between RYTM and AVGO is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.08

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Oct 6, 2017

0.23

The correlation between RYTM and AVGO shifts across timeframes, from 0.08 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

RYTM:

$5.76B

AVGO:

$2.34T

EPS

RYTM:

-$3.10

AVGO:

$5.12

PS Ratio

RYTM:

25.64

AVGO:

34.24

PB Ratio

RYTM:

702.55

AVGO:

29.33

Total Revenue (TTM)

RYTM:

$217.17M

AVGO:

$68.28B

Gross Profit (TTM)

RYTM:

$194.16M

AVGO:

$46.31B

EBITDA (TTM)

RYTM:

-$182.86M

AVGO:

$36.65B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RYTM vs. AVGO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RYTM
RYTM Risk / Return Rank: 5959
Overall Rank
RYTM Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
RYTM Sortino Ratio Rank: 6262
Sortino Ratio Rank
RYTM Omega Ratio Rank: 5858
Omega Ratio Rank
RYTM Calmar Ratio Rank: 5858
Calmar Ratio Rank
RYTM Martin Ratio Rank: 5959
Martin Ratio Rank

AVGO
AVGO Risk / Return Rank: 8484
Overall Rank
AVGO Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
AVGO Sortino Ratio Rank: 8585
Sortino Ratio Rank
AVGO Omega Ratio Rank: 8383
Omega Ratio Rank
AVGO Calmar Ratio Rank: 8282
Calmar Ratio Rank
AVGO Martin Ratio Rank: 8181
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RYTM vs. AVGO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rhythm Pharmaceuticals, Inc. (RYTM) and Broadcom Inc. (AVGO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


RYTMAVGODifference
Sharpe ratioReturn per unit of total volatility

-1.56

Sortino ratioReturn per unit of downside risk

-1.39

Omega ratioGain probability vs. loss probability

1.16

1.34

-0.19

Calmar ratioReturn relative to maximum drawdown

0.82

3.09

-2.27

Martin ratioReturn relative to average drawdown

1.96

7.42

-5.46

RYTM vs. AVGO - Sharpe Ratio Comparison

The current RYTM Sharpe Ratio is 0.51, which is lower than the AVGO Sharpe Ratio of 2.07. The chart below compares the historical Sharpe Ratios of RYTM and AVGO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


RYTMAVGODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.51

2.07

-1.56

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.47

1.46

-0.99

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

1.12

Sharpe Ratio (All Time)

Calculated using the full available price history

0.18

1.14

-0.96

Drawdowns

RYTM vs. AVGO - Drawdown Comparison

The maximum RYTM drawdown since its inception was -92.10%, which is greater than AVGO's maximum drawdown of -48.30%. Use the drawdown chart below to compare losses from any high point for RYTM and AVGO.


Loading charts...

Drawdown Indicators


RYTMAVGODifference

Max Drawdown

Largest peak-to-trough decline

-92.10%

-48.30%

-43.80%

Max Drawdown (1Y)

Largest decline over 1 year

-35.54%

-28.67%

-6.87%

Max Drawdown (3Y)

Largest decline over 3 years

-35.54%

-41.15%

+5.61%

Max Drawdown (5Y)

Largest decline over 5 years

-85.49%

-41.15%

-44.34%

Max Drawdown (10Y)

Largest decline over 10 years

-48.30%

Current Drawdown

Current decline from peak

-27.98%

-0.49%

-27.49%

Average Drawdown

Average peak-to-trough decline

-32.19%

-7.97%

-24.22%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.81%

11.91%

+2.90%

Volatility

RYTM vs. AVGO - Volatility Comparison

Rhythm Pharmaceuticals, Inc. (RYTM) has a higher volatility of 16.84% compared to Broadcom Inc. (AVGO) at 11.91%. This indicates that RYTM's price experiences larger fluctuations and is considered to be riskier than AVGO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RYTMAVGODifference

Volatility (1M)

Calculated over the trailing 1-month period

16.84%

11.91%

+4.93%

Volatility (6M)

Calculated over the trailing 6-month period

36.79%

30.70%

+6.09%

Volatility (1Y)

Calculated over the trailing 1-year period

57.37%

42.95%

+14.42%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

76.41%

42.78%

+33.63%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

70.99%

39.18%

+31.81%

Dividends

RYTM vs. AVGO - Dividend Comparison

RYTM has not paid dividends to shareholders, while AVGO's dividend yield for the trailing twelve months is around 0.52%.


PositionTTM20252024202320222021202020192018201720162015
AVGO
Broadcom Inc.
0.52%0.70%0.94%1.71%3.02%2.24%3.05%3.54%3.11%1.87%1.43%1.13%
RYTM
Rhythm Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

RYTM vs. AVGO - Financials Comparison

This section allows you to compare key financial metrics between Rhythm Pharmaceuticals, Inc. and Broadcom Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B20222023202420252026
60.11M
19.31B
(RYTM) Total Revenue
(AVGO) Total Revenue
Values in USD except per share items

RYTM vs. AVGO - Profitability Comparison

The chart below illustrates the profitability comparison between Rhythm Pharmaceuticals, Inc. and Broadcom Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
88.1%
68.1%
Portfolio components
RYTM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a gross profit of 52.96M and revenue of 60.11M. Therefore, the gross margin over that period was 88.1%.

AVGO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported a gross profit of 13.16B and revenue of 19.31B. Therefore, the gross margin over that period was 68.1%.

RYTM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported an operating income of -52.36M and revenue of 60.11M, resulting in an operating margin of -87.1%.

AVGO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported an operating income of 8.56B and revenue of 19.31B, resulting in an operating margin of 44.3%.

RYTM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rhythm Pharmaceuticals, Inc. reported a net income of -56.74M and revenue of 60.11M, resulting in a net margin of -94.4%.

AVGO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Broadcom Inc. reported a net income of 7.35B and revenue of 19.31B, resulting in a net margin of 38.1%.


Frequently Asked Questions


RYTM and AVGO have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RYTM has higher volatility (16.84%) compared to AVGO (11.91%). In terms of maximum drawdown, RYTM dropped -92.10% vs AVGO's -48.30%.

AVGO currently has the higher Sharpe Ratio (2.07 vs 0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RYTM and AVGO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer